Wuhan Hhd Pharm China Ginsenoside Ginseng Extract Purity 98% with Favourable Price Ginsenoside Rb2/RC/Rg3/Rg1/Rg3/RO/ Rb1 /RF/Re/Rg2/Rd/F1/F2/F3

Wuhan Hhd Pharm China Ginsenoside Ginseng Extract Purity 98% with Favourable Price Ginsenoside Rb2/RC/Rg3/Rg1/Rg3/RO/Rb1/RF/Re/Rg2/Rd/F1/F2/F3, Find details about China Tauroursodeoxycholic Acid, CAS 181225-33-2 from Wuhan Hhd Pharm China Ginsenoside Ginseng Extract Purity 98% with Favourable Price Ginsenoside Rb2/RC/Rg3/Rg1/Rg3/RO/Rb1/RF/Re/Rg2/Rd/F1/F2/F3

Basic Info.

Model NO.

181225-33-2

Appearance

Solid

Trademark

HENGHEDA

Transport Package

Aluminum Foil Bag

Specification

100G/BAG 1KG/BAG

Origin

China

HS Code

2932999099

Model NO.

181225-33-2

Appearance

Solid

Trademark

HENGHEDA

Transport Package

Aluminum Foil Bag

Specification

100G/BAG 1KG/BAG

Origin

China

HS Code

2932999099

Product Desciption

Product Name:	Ginsenoside Rb2/RC/Rg3/Rg1/Rg3/RO/Rb1/RF/Re/Rg2/Rd/F1/F2/F3/F4
Description:	Ginsenoside F4 has inhibitory effect on human lymphocytoma JK cell by inducing its apoptosis, the mechanism is related to the mitochondrial dysfunction and the increase of Bax expression and decrease of Bcl-2 expression. Ginsenoside F4 also has strongly inhibit activation of p38 mitogen-activated protein kinase in signal transduction pathways..
CAS:	181225-33-2
Source:	The roots of Panax ginseng C. A. Mey.
Solvent:	DMSO, Pyridine, Methanol, Ethanol, etc.

Source of Plant: China is the origin of ginseng and has 2, 000 years of medical history in China; as the rare materia medica known all around the world, it has been included in many countries Pharmacopoeia. Ginseng Panax locates in the northeast region of China, North Korea and the Far East region of the former Soviet Union.
Used Part: Extracted and refined from the Dried Root of panax ginseng

Active Ingredient: Total Ginsenosides

1)Ginsenoside Rg1
Molecular Formula :C42H72O14
Molecular Weight :801.02
CAS Number:22427-39-0

2)Ginsenoside Rb1
Molecular Formula :C54H92O23
Molecular Weight :1109.31
CAS Number:41753-43-9

3)Ginsenoside Re
Molecular Formula :C48H82O18
Molecular Weight :947.16
CAS Number:52286-59-6

Ginsenoside Rb2 11021-13-9 (75139-47-8) EYECHEM
Ginsenoside Rc 11021-14-0 EYECHEM
Ginsenoside Rg3 14197-60-5 (11019-45-7) EYECHEM
Ginsenoside Rg1 22427-39-0 EYECHEM
Dihydroginsenoside Rg3 30010-01-6 EYECHEM
Ginsenoside Ro 34367-04-9 EYECHEM
Ginsenoside Rg3 38243-03-7 EYECHEM
Ginsenoside Rb1 41753-43-9 EYECHEM
Ginsenoside Rf 52286-58-5 EYECHEM
Ginsenoside Re 52286-59-6 EYECHEM
Ginsenoside Rg2 52286-74-5 EYECHEM
Ginsenoside Rd 52705-93-8 EYECHEM
Ginsenoside F1 53963-43-2 EYECHEM
Ginsenoside F2 62025-49-4 EYECHEM
Ginsenoside F3 62025-50-7 EYECHEM
Ginsenoside Rh1 63223-86-9 EYECHEM
Ginsenoside Rb3 68406-26-8 EYECHEM
Pseudoginsenoside F11 69884-00-0 EYECHEM
Ginsenoside Rh2 78214-33-2 EYECHEM
(20R)-Ginsenoside Rh1 80952-71-2 EYECHEM
GF VII 80952-72-3 EYECHEM
Ginsenoside Ra1 83459-41-0 EYECHEM
Ginsenoside Ra2 83459-42-1 EYECHEM
Ginsenoside Ra3 90985-77-6 EYECHEM
Sanchinoside B1 97744-96-2 EYECHEM
20(R)-Ginsenoside Rh2 112246-15-8 EYECHEM
Ginsenoside Rg4 126223-28-7 EYECHEM
Ginsenoside Rg6 147419-93-0 EYECHEM
(20E)-Ginsenoside F4 181225-33-2 EYECHEM
Ginsenoside Rg5 186763-78-0 EYECHEM
Ginsenoside F5 189513-26-6 EYECHEM
(3beta,6alpha,12beta,20E)-3,12,25-Trihydroxydammar-20(22)-en-6-yl 2-O-6-deoxy-alpha-L-mannopyranosyl-beta-D-glucopyranoside 948046-19-3 EYECHEM
(3beta,12beta,20E)-12,25-Dihydroxydammar-20(22)-en-3-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside 1012886-99-5 EYECHEM
5,6-Didehydroginsenoside Rd 1268459-68-2
EYECHEM (3beta,12beta,20R)-12,20,25-Trihydroxydammaran-3-yl beta-D-glucopyranoside 1370040-12-2 EYECHEM Ginsenoside Rh10 1370264-16-6 EYECHEM
(3beta,12beta,20Z)-12,25-Dihydroxydammar-20(22)-en-3-yl beta-D-glucopyranoside 1636114-55-0 EYECHEM (3beta,12beta)-12,25-Dihydroxydammar-20(22)-en-3-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside 1945956-85-3 EYECHEM
(3beta,6alpha,12beta,20Z)-3,12,25-Trihydroxydammar-20(22)-en-6-yl 2-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside 2004673-44-1 EYECHEM
Notoginsenoside ST13 2015215-13-9 EYECHEM

In vitro:

Nat Prod Res. 2013;27(24):2351-4.

The apoptosis-inducing effect of ginsenoside F4 from steamed notoginseng on human lymphocytoma JK cells.[Pubmed: 23962295]

METHODS AND RESULTS:
In this study, the inhibitory and apoptosis-inducing effect of Ginsenoside F4 (GF4) from steamed notoginseng was investigated by using human lymphocytoma Jurkat (JK) cell. Cell Counting Kit-8 method was then used to assess the anti-proliferative effect of GF4, and Western blotting was run to detect the expression level of two apoptosis-related proteins including Bax and the Bcl-2. The results suggested that GF4 can effectively inhibit the proliferation of the cells, and Bax expression increased gradually, but Bcl-2 expression reduced with the increase of GF4 concentration.
CONCLUSIONS:
In conclusion, GF4 has inhibitory effect on human lymphocytoma JK cell by inducing its apoptosis. The mechanism of action could be related to the mitochondrial dysfunction and the increase of Bax expression and decrease of Bcl-2 expression by GF4.

Eur J Pharmacol. 2014 Feb 5;724:145-51.

Ginsenosides from Korean red ginseng inhibit matrix metalloproteinase-13 expression in articular chondrocytes and prevent cartilage degradation.[Pubmed: 24384406]

Among the mammalian matrix metalloproteinases (MMPs), MMP-1, -3 and -13 are collagenases. Particularly, MMP-13 is important for the degradation of major collagens in cartilage under certain pathological conditions such as osteoarthritis.
METHODS AND RESULTS:
To establish a potential therapeutic strategy for cartilage degradation disorders, the effects of 11 ginseng saponins (ginsenosides Rb1, Rb2, Rc, Rd, Re, Rf, Rg1, Rg3, Rg5, Rk1 and F4) on MMP-13 induction were examined in a human chondrocyte cell line, SW1353. Among these, several saponins including ginsenoside Rc, Rd, Rf, Rg3 and F4 were found to inhibit MMP-13 expression in IL-1β-treated SW1353 cells at non-cytotoxic concentrations (1-50 μM). The most prominent inhibitors were ginsenosides F4 and Rg3. Ginsenoside F4 inhibited MMP-13 expression 33.5% (P<0.05), 57.9% (P<0.01) and 90.0% (P<0.01) at 10, 30 and 50 μM, respectively. Significantly, Ginsenoside F4 was found to strongly inhibit activation of p38 mitogen-activated protein kinase in signal transduction pathways (86.6 and 100.0% inhibition at 30 and 50 μM, P<0.01). The MMP-13 inhibitory effect was also supported by the finding that ginsenosides F4 and Rg3 reduced glycosaminoglycan release from IL-1α-treated rabbit joint cartilage culture to some degree. Taken together, these results indicate that several ginsenosides inhibit MMP-13 expression in IL-1β-treated chondrocytes. Ginsenoside F4 and Rg3 blocked cartilage breakdown in rabbit cartilage tissue culture.
CONCLUSIONS:
Thus, it is suggested that certain ginsenosides have therapeutic potential for preventing cartilage collagen matrix breakdown in diseased tissues such as those found in patients with arthritic disorders.